viewTiziana Life Sciences PLC

Tiziana Life Sciences to conduct COVID-19 human clinical study in Brazil using its “potentially transformative approach” to modulating the immune system

  • The company will be dosing humans "in weeks" - well ahead of schedule
  • Initial data read-out expected by the end of the year
Tiziana Life Sciences PLC -

This is a huge milestone for the company as we have brought the time-line forward by a year

Chairman Gabriele Cerrone

Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) has signed an agreement to use its “potentially transformative” approach to modulating the immune system in a human clinical study of patients with coronavirus (COVID-19).

Work will get underway in Brazil starting next month, with the company's drug, Foralumab, administered by nasal spray either on its own or in combination with an orally-taken anti-inflammatory called dexamethasone.

Tiziana has moved straight into human trials because it had already secured safety data for the nasal application for the drug from a phase I clinical assessment carried out a year ago.

"This is a huge milestone for the company as we have brought the time-line forward by getting it [the drug] into patients one year ahead of schedule," chairman Gabriele Cerrone said in an interview with Proactive's Andrew Scott, carried below. 

The fully human anti-CD3 monoclonal antibody is being deployed to suppress an overreaction of the immune system called a cytokine storm that occurs in those worst-affected by the virus.

In doing so it is hoped it will reduce respiratory failure, the main underlying cause of COVID-19 deaths.

The drug developer, which on Wednesday formalised plans to demerge its diagnostics business, said the clinical study will start in the next few weeks with data anticipated before the end of the year.

It pointed out that it has developed a “robust formulation” for the delivery of Foralumab using a nasal spray.

There were also early signs from its phase I trial that the Tiziana drug and delivery system stimulated regulatory T-cells, or Tregs, that help control other cells in the immune system.

“Nasal administration of Foralumab to modulate human immune system is a potentially transformative approach for treating patients with a variety of human diseases with dysregulated immune system,” said Dr Howard Weiner, a world-leading neurologist and chairman of Tiziana’s scientific advisory board in a statement.  

“Results from studies, conducted in our laboratory have established that nasal administration of anti-CD3 induces Tregs that suppress inflammation and ameliorate diseases in animal models.”

The shares were up 8.7% at 160p in early afternoon trade.

---adds share price---

Quick facts: Tiziana Life Sciences PLC

Price: 173 GBX

Market: AIM
Market Cap: £331.19 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...


Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

on 09/22/2020

2 min read